| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
TScan Therapeutics, Inc. (NASDAQ:TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced a poster presentation at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition. The poster highlights initial data from the Phase 1 multi-arm clinical trial evaluating TSC-100 and TSC-101, which are designed to treat residual disease and prevent relapse following hematopoietic cell transplantation (HCT) in patients with acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), or acute lymphocytic leukemia (ALL) (NCT05473910).
No relapses have occurred in six of six treatment-arm patients, four with follow-up past six months; one of four control-arm patients relapsed at six months and two others required clinical intervention
No patient-derived hematopoietic cells detected in six of six treatment-arm patients, indicating complete elimination of target cells, versus zero of four control-arm patients
AML patient with detectable disease post-transplant converted to no detectable disease following treatment with TSC-101
Patients enrolled up to the third and final dose level in both treatment arms with no dose limiting toxicities
Company to host virtual KOL event on Monday, December 11, at 8:00 a.m. ET to discuss the data presented at the ASH Annual Meeting and Exposition
Posted In: TCRX
